Reconsidering Prostate Cancer Mortality — The Future of PSA Screening | NEJM

Reconsidering Prostate Cancer Mortality — The Future of PSA Screening | NEJM: Medicine and Society from The New England Journal of Medicine — Reconsidering Prostate Cancer Mortality — The Future of PSA Screening

New 'toolbox' for urological cancer detection -- ScienceDaily

New 'toolbox' for urological cancer detection -- ScienceDaily: Researchers have developed a new method for biomarker discovery of urological cancers. The method enables timely diagnosis and treatment of cancer. Urological cancers include e.g. prostate, bladder and kidney cancers.

Judd W. Moul, MD, FACS, on Triaging Patients with Prostate Cancer | Cancer Network

Judd W. Moul, MD, FACS, on Triaging Patients with Prostate Cancer | Cancer Network: The prostate cancer expert discussed guidelines that he and his colleagues culminated for triaging patients with prostate cancer during the COVID-19 pandemic.

Reconsidering Prostate Cancer Mortality — The Future of PSA Screening | NEJM

Reconsidering Prostate Cancer Mortality — The Future of PSA Screening | NEJM: Medicine and Society
Reconsidering Prostate Cancer Mortality — The Future of PSA Screening
List of authors.

H. Gilbert Welch, M.D., M.P.H., and Peter C. Albertsen, M.D.

Article
Figures/Media

Metrics

23 References

From its peak in the early 1990s, U.S. mortality due to prostate cancer has decreased from 39 per 100,000 men to 19 per 100,000 men — essentially by half. Although everyone agrees that this reduction is good news, there is considerable disagreement about why it happened. The controversy has profound implications for the future of prostate-specific antigen (PSA) screening.
Figure 1. Prostate Cancer Mortality in the United States, 1950–2016.

A long-term perspective on trends in cancer-specific mortality among patients with three common causes of cancer-related deaths since 1950 is provided in Figure 1A. The substantial rise and fall in the largest component of cancer-related mortality, lung cancer mortality, reflects the rise and fall in rates of cigarette smoking decades earlier. In contrast, breast cancer mortality was remarkably stable until 1990 and then began to fall. Prostate cancer mortality was similarly stable until 1970 and als

miR‐30a inhibits androgen‐independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4 - Li - - The Prostate - Wiley Online Library

miR‐30a inhibits androgen‐independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4 - Li - - The Prostate - Wiley Online Library: Background
Castrate‐resistant prostate cancer (CRPC) is an aggressive and lethal disease. The pathogenesis of CRPC is not fully understood and novel therapeutic targets need to be identified to impr...

Integrative analysis of AR‐mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression - Cheng - - The Prostate - Wiley Online Library

Integrative analysis of AR‐mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression - Cheng - - The Prostate - Wiley Online Library: Background
Androgen receptor (AR) is crucial for prostate cancer (PCa) initiation and malignant progression. Only half of androgen‐responsive genes have been identified as having androgen‐responsive...

Costs and Complications after a Diagnosis of Prostate Cancer Treated with Time-Efficient Modalities: an Analysis of National Medicare Data - ScienceDirect

Costs and Complications after a Diagnosis of Prostate Cancer Treated with Time-Efficient Modalities: an Analysis of National Medicare Data - ScienceDirect: Recent trends in payer and patient preferences increasingly incentivize time-efficient (≤2 weeks treatment time) prostate cancer treatments.National M…

Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer | Prostate Cancer and Prostatic Diseases

Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer | Prostate Cancer and Prostatic Diseases: Metastatic disease burden out of proportion to serum PSA has been used as a marker of aggressive phenotype prostate cancer but is not well defined as a distinct subgroup. We sought to prospectively characterize the molecular features and clinical outcomes of Low PSA Secretors. Eligible metastatic castration resistant prostate cancer (mCRPC) patients without prior small cell histology underwent metastatic tumor biopsy with molecular characterization. Low PSA secretion was defined as serum PSA < 2, 5, or 10 ng/mL plus >5 metastases with radiographic progression at study entry. Clinical and molecular features were compared between low PSA vs. normal secretors in a post-hoc fashion. 183 patients were enrolled, including 15 (8%) identified as Low PSA Secretors using optimal PSA cut point of 5 ng/mL. Biopsies from Low PSA Secretors demonstrated higher t-SCNC and RB1 loss and lower AR transcriptional signature scores compared with normal secretors. Genomic loss of RB1 and/or TP53 was more common in Low PSA Secretors (80% vs. 41%). Overall survival (OS) was shorter in Low PSA Secretors (median OS = 26.7 vs. 46.0 months, hazard ratio = 2.465 (95% CI: 0.982–6.183). Progression-free survival

Mathematical model predicts patient outcomes to adaptive therapy -- ScienceDaily

Mathematical model predicts patient outcomes to adaptive therapy -- ScienceDaily: Researchers provide a closer look at a mathematical model and data showing that individual patient alterations in the prostate-specific antigen (PSA) biomarker early in cancer treatment can predict outcomes to later treatment cycles of adaptive therapy.

Patients of Metastatic Prostate Cancer Could Benefit from Immunotherapy Treatment | Cancer Network

Patients of Metastatic Prostate Cancer Could Benefit from Immunotherapy Treatment | Cancer Network: A recent study found that a group of patients with metastatic castration-resistant prostate cancer responded positively to treatment with ipilimumab, prolonging survival after treatment in the “favorable” cohort.

Prostatepedia Digest

Prostatepedia Digest

Cancer scientists aim to use protein power to stop tumor growth -- ScienceDaily

Cancer scientists aim to use protein power to stop tumor growth -- ScienceDaily: Scientists have created a new therapy option that may help halt tumor growth in certain cancers such as prostate, which is among the most common types of cancer in men.

Managing Treatment for Patients with Prostate Cancer During the COVID-19 Pandemic | Cancer Network

Managing Treatment for Patients with Prostate Cancer During the COVID-19 Pandemic | Cancer Network: An international team of researchers created a framework of recommendations to help patients and healthcare professionals make decisions regarding radiation treatment for patients with prostate cancer during the COVID-19 pandemic.

Combined Biopsy Strategy Improved Prostate Cancer Diagnosis | MedPage Today

Combined Biopsy Strategy Improved Prostate Cancer Diagnosis | MedPage Today: Combo biopsy missed only 3.5% of the most aggressive cancers

A Mobile App for Cancer Thrivers During the Coronavirus Pandemic — Cancer ABCs

A Mobile App for Cancer Thrivers During the Coronavirus Pandemic — Cancer ABCs: Today, our partners at Stand Up To Cancer announced an initiative that will both help scientists understand the emerging coronavirus pandemic and ensure the needs of cancer patients and survivors are being included as the research goes forward.